Nutley, Sara K.
Read, Michael
Martinez, Stephanie
Eichenbaum, Joseph
Nosheny, Rachel L.
Weiner, Michael
Mackin, R. Scott
Mathews, Carol A.
Funding for this research was provided by:
National Institutes of Health (R01MH117114, R01MH117114)
Article History
Received: 15 June 2022
Accepted: 30 September 2022
First Online: 15 October 2022
Declarations
:
: Ethical approval was received from the Institutional Review Boards at the University of California San Francisco and the University of Florida. All participants provided electronic informed consent prior to enrollment in the Brain Health Registry. This investigation was conducted in accordance with relevant guidelines and regulations.
: Not applicable.
: CM has received royalties from W.W. Norton and Company, and travel funding from the Tourette Association of America. She has received research funding from the National Institutes of Health, the International Obsessive Compulsive Foundation, the Tourette Association of America, and the Patient Centered Research Outcomes Institute. She is an unpaid member of several advisory boards, including the Tourette Association of America, the International OCD Foundation, and the Family Foundation for OCD Research. RSM has received research funding from the National Institutes of Health and Janssen Research and Development LLC. RN has received research funding from the National Institutes of Health and Genentech, Inc., and travel funding from Mount Sinai Medical Center. MW has served on Advisory Boards for Eli Lilly, Cerecin/Accera, Roche, Alzheon, Inc., Merck Sharp & Dohme Corp., Nestle/Nestec, PCORI/PPRN, Dolby Family Ventures, National Institute on Aging (NIA), Brain Health Registry and ADNI. MW serves on the Editorial Boards for Alzheimer’s & Dementia, TMRI and MRI. He has provided consulting and/or acted as a speaker/lecturer to Cerecin/Accera, Inc., BioClinica, Nestle/Nestec, Roche, Genentech, NIH, The Buck Institute for Research on Aging, FUJIFILM-Toyama Chemical (Japan), Garfield Weston, Baird Equity Capital, University of Southern California (USC), Cytox, and Japanese Organization for Medical Device Development, Inc. (JOMDD) and T3D Therapeutics. MW holds stock options with Alzheon, Inc., Alzeca, and Anven. MW receives support for his work from the National Institutes of Health, Department of Defense, Patient-Centered Outcomes Research Institute, the California Dept. of Public Health, The University of Michigan, Siemens, Biogen, Hillblom Foundation, the Alzheimer’s Association, the State of California, Johnson and Johnson, Kevin and Connie Shanahan, GE, VUmc, Australian Catholic University, The Stroke Foundation and the Veterans Administration. SN, MR, SM, and JE declare that they have no competing interests.